ArticleScientific reports2025
Exosomal miR-92a-3p serves as a promising marker and potential therapeutic target for adenomyosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Applications of Exosomes in Female Medicine: A Systematic Review of Molecular Biology, Diagnostic and Therapeutic Perspectives.International journal of molecular sciences · 2026Pooled it
- Non-Coding RNAs (microRNAs, lncRNAs, circRNAs) in Adenomyosis: A Systematic Review of Mechanistic and Translational Evidence.International journal of molecular sciences · 2025Pooled it
- Circulating plasma microRNAs as potential non-invasive biomarkers in infertile women with adenomyosis: an observational study.Reproductive biology and endocrinology : RB&E · 2026Observational
- MicroRNAs as Biomarkers for Adenomyosis: A Systematic Review.Biomedicines · 2026Review
- Increased Junctional Zone Stiffness and Serum Small Extracellular Vesicle Proteomic Signatures in Adenomyosis-Associated Infertility: An Exploratory SWE and Proteomic Study.International journal of women's health · 2026Article
- Analysis and validation of novel biomarkers related to palmitoylation in adenomyosis.Frontiers in genetics · 2025Article
- Role of extracellular vesicles in cancer: implications in immunotherapeutic resistance.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study aimed to elucidate the role of microRNA-92a-3p (miR-92a-3p) in the pathogenesis of adenomyosis. We examined how miR-92a-3p, found in exosomes derived from ectopic lesions, influences the behaviour of endometrial cells, dorsal root ganglion (DRG), and human umbilical vein endothelial cells (HUVECs) and explored its potential as a non-invasive biomarker. Our findings revealed that miR-92a-3p was significantly upregulated in exosomes derived from ectopic adenomyotic lesions. This upregulation correlated with enhanced migration and invasion of eutopic endometrial cells, DRG, and HUVECs. Furthermore, this study demonstrated a significant correlation between miR-92a-3p levels in urinary exosomes and the clinical symptoms of adenomyosis, suggesting its potential as a non-invasive biomarker for the disease. This study elucidated an exosomal signalling process involving miR-92a-3p that drives pathological infiltration and angiogenesis to promote adenomyosis progression. Our findings highlight upregulated miR-92a-3p in biofluid exosomes as a promising non-invasive biomarker for diagnosing and monitoring adenomyosis and unveil novel targets and strategies for improved clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.